SCHEMBL24252943

SCHEMBL24252943

CCOc1cc(Br)c(C)cc1C=O

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.67
POLB P06746 1/20 0.50
ALDH1A1 P00352 10/20 0.44
KDM4E B2RXH2 2/20 0.44
PRKDC P78527 1/20 0.44
TSHR P16473 3/20 0.44
HSD17B10 Q99714 1/20 0.44
HPGD P15428 4/20 0.40
MAPT P10636 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.36
TDP1 Q9NUW8 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HTT P42858 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12937302 0.83 LMNA (0.46) LMNAPOLBKDM4EPRKDCGAA
SCHEMBL7797947 0.82 LMNA (0.66) LMNAPOLBALDH1A1KDM4EPRKDC
SCHEMBL29771752 0.82 LMNA (0.66) LMNAPOLBALDH1A1KDM4EPRKDC
SCHEMBL24311177 0.82 LMNA (0.45) LMNAPOLBALDH1A1KDM4EPRKDC
SCHEMBL22244892 0.81 LMNA (0.65) LMNAPOLBALDH1A1KDM4EPRKDC
SCHEMBL23783245 0.81 LMNA (0.70) LMNAPOLBALDH1A1KDM4EPRKDC
SCHEMBL10969853 0.81 LMNA (0.68) LMNAPOLBALDH1A1KDM4EPRKDC
SCHEMBL24311262 0.81 LMNA (0.44) LMNAPOLBALDH1A1KDM4EPRKDC
SCHEMBL31456072 0.80 PRKDC (0.63) LMNAPOLBALDH1A1KDM4EPRKDC
SCHEMBL15031973 0.80 PRKDC (0.63) LMNAPOLBALDH1A1KDM4EPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303494-A1 BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF ACADEMY OF MILITARY MEDICAL SCIENCES (CN) 2023-09-28 US disclosed
US-20230303494-A1 BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF ACADEMY OF MILITARY MEDICAL SCIENCES (CN) 2023-09-28 US disclosed
EP-4198017-A1 BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Academy of Military Medical Sciences (CN) 2023-06-21 EP disclosed
WO-2022033303-A1 BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 中国人民解放军军事科学院军事医学研究院 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303494-A1 BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CD274, PDCD1, PDCD1LG2 LMNA 2409/4885POLB 3163/4885ALDH1A1 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.